Stock Analysis
Beta Bionics, Inc. (BBNX) Stock Analysis
Beta Bionics, Inc. (BBNX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Beta Bionics, Inc. (BBNX) currently has an AIQ Score of 54/100, indicating a neutral setup. Momentum is the strongest factor at 72/100. Risk is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BBNX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $14.33 |
| AIQ Score | 54/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $764.22M |
| P/E Ratio (TTM) | -7.87 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.52 |
| Revenue (Q3 FY2026) | $35.51M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.47 |
| Volume | 1.38M |
| 52-week range | $8.80-$32.71 |
| RSI 14 | 45.53 |
| 50-Day SMA | $18.47 |
| 200-Day SMA | $14.82 |
| Analyst Price Target | $24.60 |
| Next Earnings | Feb 16, 2027 |
BBNXBeta Bionics, Inc.
Healthcare / Medical - Devices
Low Priority
In Line With Peers
Latest quote
- Momentum72
- Value39
- Quality53
- Risk resilience36
- Sentiment—
BBNX Stock Analysis Summary
Beta Bionics, Inc. (BBNX) currently has an AIQ Score of 54/100, indicating a neutral setup. Momentum is the strongest factor at 72/100. Risk resilience is the weakest current factor at 36/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, BBNX has AIQ Score of 54/100 with Momentum base of 72/100 and fading Risk resilience at 36/100. Wait for component alignment before adding exposure.
Momentum (72/100) leads while Risk resilience (36/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.65% stock move · BBNX classified in Medical - Devices.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BBNX Bullish or Bearish Right Now?
BBNX currently has a neutral overall setup. Momentum is the strongest factor at 72/100, while Risk Resilience is weakest at 36/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 72/100.
- - Analyst target implies +71.67% upside from the latest quote.
- - Value is the current constraint at 39/100.
- - Risk Resilience is weak at 36/100.
- - Technical consensus has more sell votes than buy votes (31 vs 5).
Current Consensus
BBNX's Technical Analysis Consensus is currently Strong Sell, with 5 buy, 10 neutral, and 31 sell votes. BBNX's 14-day RSI is 45.53, which places the stock in a neutral momentum range. BBNX's beta is 1.47, indicating greater market sensitivity than the broad market.
What Changed in BBNX?
The largest recent change in BBNX is Momentum moving down by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the BBNX Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BBNX Decision Framework
Public evidence layers, setup checks, and risk context for Beta Bionics, Inc..
Beta Bionics, Inc. (BBNX) Stock Analysis
Beta Bionics, Inc. has an AIQ Score of 54/100 in a Neutral regime. Momentum is strongest at 72/100. Beta is 1.47, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BBNX is in a Neutral AIQ regime with score 54/100. |
| Signal Conflict | The primary conflict is that momentum leads at 72/100 while risk lags at 36/100. |
| Factor Evidence | Momentum 72/100 · Value 39/100 · Quality 53/100 · Risk 36/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 72/100.
Momentum is 72/100 and RSI (14) is 45.5.
BBNX is in a Neutral regime at 54/100.
Risk factor is 36/100 with beta 1.47 and annual volatility 84.66%.
Current conflict: momentum leads at 72/100 while risk lags at 36/100.
BBNX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BBNX Fundamentals
BBNX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BBNX Technical Analysis
BBNX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BBNX Stock Catalysts
Track BBNX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BBNX Dividend Analysis
BBNX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BBNX Financial Data
BBNX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BBNX Risk Analysis
BBNX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BBNX Stock News
BBNX stock news, market tone, recent headlines, and catalyst context.
BBNX vs Medical - Devices Peers
Current peer cohort: BBNX · BFLY · BIO · BRKR · CNMD. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BBNX Current stock | 54/100 | 39/100 | 72/100 | 36/100 | -0.16 | 84.66% | Current |
| BFLY Butterfly Network, Inc. | 47/100 | 29/100 | 63/100 | 32/100 | 1.4 | 121.33% | BBNX vs BFLY |
| BIO Bio-Rad Laboratories, Inc. | 73/100 | 80/100 | 79/100 | 74/100 | 0.47 | 36.18% | BBNX vs BIO |
| BRKR Bruker Corporation | 64/100 | 53/100 | 83/100 | 44/100 | 0.89 | 59.79% | BBNX vs BRKR |
| CNMD CONMED Corporation | 71/100 | 84/100 | 74/100 | 58/100 | 0.48 | 46.99% | BBNX vs CNMD |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for BBNX: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 19, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BBNX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BBNX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BBNX Stock FAQ
What is BBNX stock price today?
Beta Bionics, Inc.'s current stock price is $14.33. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BBNX bullish or bearish right now?
BBNX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BBNX's market cap?
BBNX's market cap is $764.22M based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BBNX's current P/E ratio?
BBNX's current P/E ratio is -7.87 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BBNX's RSI?
BBNX's 14-day RSI is 45.53 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BBNX above its 50-day and 200-day moving averages?
BBNX is -11.10% from its 50-day SMA and 10.82% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BBNX's next earnings date?
BBNX's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BBNX pay a dividend?
BBNX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.